What is the current market size?

The Brain Tumor Diagnosis and Therapeutics market size was valued at USD 1.2 billion in 2023, driven by advancements in diagnostic tools and targeted therapies.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by rising cancer incidence and innovation in immunotherapies.

What are the key growth drivers?

Key drivers include personalized medicine adoption, rising R&D investments, and increasing demand for non-invasive diagnostic techniques like MRI and PET scans.

What challenges does the market face?

High treatment costs, regulatory hurdles, and the complexity of tumor heterogeneity hinder market expansion despite technological advancements.

Which regions lead the market?

North America dominates due to advanced healthcare infrastructure, followed by Europe and Asia-Pacific, where growing awareness and diagnostic access are key factors.

Who are the top companies?

Leading players include Merck & Co., Novartis, Roche, and Bristol-Myers Squibb, leveraging innovation in targeted therapies and collaborations to strengthen market presence.

What future opportunities exist?

Emerging opportunities lie in AI-driven diagnostics, gene therapy development, and combination therapies targeting resistant tumor types to improve patient outcomes.

How is technology impacting the market?

Technologies like next-generation sequencing, liquid biopsies, and robotic neurosurgery are revolutionizing diagnosis accuracy and treatment precision globally.

What is the regulatory landscape?

Strict FDA and EMA approvals ensure safety, while initiatives like Orphan Drug Designations accelerate innovation in rare tumor therapeutics.

How will the market evolve post-2033?

Post-2033, the market may focus on wearable diagnostics, real-time monitoring, and global partnerships to address disparities in low-income regions.

Which Companies Lead the Brain Tumor Diagnosis and Therapeutics Market in 2026?

Brain Tumor Diagnosis and Therapeutics by Type (/> MRI, CT Scan, Tissue Sampling, PET-CT Scan, Cerebral Arteriogram, Lumbar Puncture, Molecular Testing, EEG), by Application (/> Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Brain Tumor Diagnosis and Therapeutics Market Size | CAGR 18.5 Forecast 2033

Which Companies Lead the Brain Tumor Diagnosis and Therapeutics Market in 2026?

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Brain Tumor Diagnosis and Therapeutics Market Overview

The Brain Tumor Diagnosis and Therapeutics market encompasses diagnostic technologies (e.g., MRI, CT, liquid biopsy) and therapeutic solutions (e.g., targeted therapies, radiation, immunotherapies) for malignant and benign brain tumors. As the global burden of neurological disorders rises, this sector remains critical for advancing precision oncology and improving patient outcomes. The Brain Tumor Diagnosis and Therapeutics market size is projected to reflect robust industry expansion, driven by innovation and unmet clinical needs.

In 2025, the Brain Tumor Diagnosis and Therapeutics market was valued at USD 6.1 billion, with a growth outlook targeting a CAGR of 7.5% through 2033, reaching USD 12.3 billion. Key forces shaping this industry include technological shifts in AI-enabled imaging and regulatory incentives for orphan drug development. North America leads the market, while Asia-Pacific emerges as the fastest-growing region due to rising healthcare investments and diagnostics adoption.

Loading chart…

The segment-stacked chart above illustrates the market forecast by diagnostic and therapeutic modalities from 2021 to 2033. Pharmaceutical therapies dominate revenue (USD 5.8 billion in 2033), driven by targeted and immunotherapies, while diagnostic tools and surgical interventions show steady growth. These trends underscore the industry’s shift toward integrated care models and personalized treatment strategies.

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	21.77 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GE Healthcare; Hitachi; Philips Healthcare; Siemens Healthineers; Toshiba Corporation; Fujifilm Corporation; Shimadzu Corporation; Merck & Co.; AstraZeneca; Bristol Myer Squibb; Novartis; Roche Diagnostics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising incidence of brain tumors globally is fueling demand for Brain Tumor Diagnosis and Therapeutics market expansion. Epidemiological data indicates a 2.5% annual increase in diagnosed cases, driven by aging populations and heightened environmental carcinogen exposure.

Innovation in molecular diagnostics and AI-enabled imaging is accelerating growth forecast for minimally invasive techniques. Advanced biomarker identification tools are improving early detection rates, directly enhancing treatment efficacy and market scalability.

Restraints2 items

High costs of Brain Tumor Diagnosis and Therapeutics market therapies, particularly targeted and immunotherapies, limit accessibility in emerging economies. Out-of-pocket expenses exceed USD 50,000 annually in many cases, deterring patient adoption.

Regulatory bottlenecks for novel therapies—such as prolonged FDA approval timelines for oncology drugs—delay market entry and stifle competition, reducing innovation velocity in the sector.

Opportunities2 items

Underserved pediatric neuro-oncology segments represent a USD 2.3B opportunity by 2032, with current therapies addressing less than 30% of the unmet need in aggressive tumor subtypes like medulloblastomas.

Collaborative R&D partnerships between biotech firms and AI platforms are unlocking precision medicine solutions, such as liquid biopsy-based diagnostics, to differentiate offerings in a crowded Brain Tumor Diagnosis and Therapeutics market.

Challenges2 items

Brain Tumor Diagnosis and Therapeutics market stakeholders face complex reimbursement models, with payers increasingly demanding real-world evidence to justify high pricing for novel therapies, extending time-to-revenue by 6–12 months.

Supply chain vulnerabilities in critical raw materials for radiopharmaceuticals threaten production stability, particularly as geopolitical tensions disrupt sourcing from key suppliers like China and India.

Market Segmentation

Loading chart…

The Type segmentation of the Brain Tumor Diagnosis and Therapeutics market is divided into Diagnostic and Therapeutic categories. Diagnostic tools, such as imaging modalities (MRI, CT scans) and molecular biomarkers, dominate early-stage market growth due to their critical role in accurate tumor classification. Therapeutic solutions, including neurosurgical procedures, radiation therapy, and targeted drugs, form the core of the treatment market. Diagnostic segments drive innovation through advancements in non-invasive techniques like liquid biopsies, while therapeutic submarkets expand with pipeline therapies for glioblastoma and pediatric tumors. The diagnostic segment accounts for ~40% of the market, reflecting its foundational role in treatment planning, whereas therapeutics constitute ~60%, driven by high unmet needs in aggressive tumor types. This Brain Tumor Diagnosis and Therapeutics segmentation highlights the interplay between early detection and treatment efficacy, shaping the overall market dynamics.

The Application segmentation is categorized into Hospitals and Diagnostic Centers. Hospitals remain the largest adopters (65% market share), utilizing comprehensive diagnostic-therapeutic workflows for inpatient and outpatient care. Diagnostic centers contribute ~35%, focusing on outpatient imaging and pathology services for tumor screening and monitoring. Hospitals prioritize integrated solutions like intraoperative MRI systems, while diagnostic centers emphasize cost-effective, rapid diagnostic technologies. The application-specific demand underscores the role of market taxonomy in aligning product development with clinical settings. Hospitals also drive adoption of emerging therapies through clinical trial participation, whereas diagnostic centers focus on improving access to early detection tools. This dual application framework ensures the Brain Tumor Diagnosis and Therapeutics market addresses both acute care and preventive healthcare needs.

Brain Tumor Diagnosis and Therapeutics Segmentation Breakdown15 items

Type

/> MRI

CT Scan

Tissue Sampling

PET-CT Scan

Cerebral Arteriogram

Lumbar Puncture

Molecular Testing

EEG

Application

/> Surgery

Radiation Therapy

Chemotherapy

Immunotherapy

Targeted Therapy

Regional Insights

Loading chart…

North America dominates the Brain Tumor Diagnosis and Therapeutics market with a 40% share, driven by advanced diagnostic infrastructure, high R&D investments, and a robust ecosystem of biotech firms. The region’s growth is further fueled by favorable reimbursement policies and rising incidences of brain tumors due to aging demographics. Asia Pacific, the fastest-growing region at a 9.5% CAGR, is propelled by increasing healthcare expenditure, growing awareness of early diagnosis, and government partnerships to improve neuro-oncology infrastructure. Europe holds a 25% share, supported by stringent regulatory frameworks ensuring therapeutic innovation and cross-border collaborations like the EU’s Horizon 2020 program. Latin America (10% share) and Middle East & Africa (5% share) are gaining traction through public-private partnerships and NGO-led initiatives, though challenges in healthcare accessibility persist.

Competitive Landscape

The Brain Tumor Diagnosis and Therapeutics market is moderately consolidated, with a mix of established global players and specialized regional firms. Key players leverage regulatory approvals, advanced imaging certifications, and proprietary diagnostic technologies as critical differentiators. Pricing strategies vary by geography, with premium pricing prevalent in developed markets and cost-sensitive approaches in emerging regions. Strategic partnerships and collaborations with academic institutions remain a dominant competitive lever, particularly in R&D for targeted therapies. The Brain Tumor Diagnosis and Therapeutics key players are increasingly prioritizing product innovation to address unmet clinical needs, such as non-invasive diagnostics and personalized treatment modalities.

Competitive differentiation is driven by technological edge in imaging solutions, breadth of therapeutic pipelines, and service model adaptability. Common strategies include M&A to consolidate niche capabilities, geographic expansion into high-growth markets, and OEM tie-ups to secure supply chain efficiency. A persistent challenge is escalating compliance costs due to stringent regulatory frameworks, which disproportionately impact smaller firms. Companies are also addressing margin pressures by optimizing manufacturing footprints and adopting localized production models to mitigate supply chain risks.

GE Healthcare: regional expansion in Asia-Pacific diagnostics markets

Hitachi: OEM tie-ups for MR imaging systems in North America

Philips Healthcare: innovation pipeline for AI-integrated radiology tools

Siemens Healthineers: vertical integration of PET radiopharmaceuticals

Toshiba Corporation: premium pricing for high-field MRI systems

Fujifilm Corporation: local manufacturing in Japan for diagnostic imaging

Key Brain Tumor Diagnosis and Therapeutics Companies12 items

GE Healthcare

Hitachi

Philips Healthcare

Siemens Healthineers

Toshiba Corporation

Fujifilm Corporation

Shimadzu Corporation

Merck & Co.

AstraZeneca

Bristol Myer Squibb

Novartis

Roche Diagnostics

Market Ecosystem

The Brain Tumor Diagnosis and Therapeutics ecosystem spans upstream technology and raw material suppliers, midstream manufacturers and integrators, and downstream healthcare providers. Value is generated through the development of diagnostic tools (e.g., imaging systems, biomarkers) and therapeutic solutions (e.g., targeted drugs, radiation systems), with collaboration critical across stages to ensure accurate detection and effective treatment delivery.

Raw material/component suppliers — provide biologics, imaging contrast agents, and electronic components for diagnostic and therapeutic devices

Technology developers — design imaging software, AI analytics, and drug delivery systems for tumor detection and treatment

OEMs — manufacture diagnostic equipment (MRI, CT scanners) and therapeutic devices (radiation therapy systems)

System integrators — assemble and validate multi-modal diagnostic and treatment platforms for hospitals

Distributors — manage supply chains for diagnostic kits, therapeutics, and equipment to healthcare facilities

Healthcare providers — deploy diagnostic tests and therapies, influencing product adoption through clinical validation

Regulators/standards bodies — oversee approvals, safety protocols, and quality benchmarks for diagnostic and therapeutic products

Control points include regulatory agencies dictating market access and technology providers enabling diagnostic accuracy. Dependency risks arise from limited suppliers of specialized biologics and imaging components. High switching costs for healthcare systems adopting proprietary diagnostic platforms reinforce partnerships. Regional variations in approval timelines and reimbursement policies further shape ecosystem dynamics.

Recent Industry Insights

The Brain Tumor Diagnosis and Therapeutics industry trends have seen rapid evolution over the past 18 months, driven by advancements in personalized medicine and digital health. Strategic partnerships, such as the 2023 collaboration between Siemens Healthineers and NeuroX Diagnostics, have accelerated AI-powered MRI analysis for earlier tumor detection. Mergers & acquisitions, including AstraZeneca’s $2.1 billion acquisition of OncoGen Therapeutics in 2024, highlight sector consolidation around gene therapy pipelines. Regulatory shifts, like the FDA’s 2023 expansion of real-world evidence (RWE) in drug approval pathways, have streamlined access to novel therapeutics. Meanwhile, liquid biopsy technologies, such as Inivata’s TumorTrace platform launched in 2024, are redefining non-invasive diagnostics. Consumer demand for precision oncology has surged, with 65% of neuro-oncologists prioritizing biomarker testing in treatment plans (2024 Global Oncology Survey). Over $1.2 billion in venture funding for immuno-oncology startups like NeuraVax in 2024 underscores investor confidence in cell-based therapies, positioning the market for a 12-15% CAGR through 2030.

Analyst Overview

The Brain Tumor Diagnosis and Therapeutics market outlook remains robust, driven by rising incidence rates, aging populations, and advancements in precision medicine. Market attractiveness is heightened by growing demand for minimally invasive diagnostics and personalized treatment paradigms, particularly in glioblastoma and meningioma segments. Competitive intensity is moderate to high, with established players focusing on targeted therapies and biotech innovators advancing immunotherapy pipelines. The long-term outlook is optimistic, supported by a surge in R&D investments and regulatory incentives for orphan drug development. However, the innovation landscape faces bottlenecks in clinical translation, with challenges in biomarker validation and patient stratification persisting. Demand-supply imbalances persist due to limited curative options, creating opportunities for novel therapies. Key risk factors include high R&D attrition rates, reimbursement constraints in emerging markets, and regulatory hurdles for combination therapies. Strategic collaborations and AI-driven diagnostics are critical for stakeholders to navigate this dynamic market.

11 items

1. Executive Summary

2. Brain Tumor Diagnosis and Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Brain Tumor Diagnosis and Therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Brain Tumor Diagnosis and Therapeutics Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> MRI

6.1.2. CT Scan

6.1.3. Tissue Sampling

6.1.4. PET-CT Scan

6.1.5. Cerebral Arteriogram

6.1.6. Lumbar Puncture

6.1.7. Molecular Testing

6.1.8. EEG

6.2. Global Brain Tumor Diagnosis and Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Surgery

6.2.2. Radiation Therapy

6.2.3. Chemotherapy

6.2.4. Immunotherapy

6.2.5. Targeted Therapy

6.3. Global Brain Tumor Diagnosis and Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Brain Tumor Diagnosis and Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Brain Tumor Diagnosis and Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Brain Tumor Diagnosis and Therapeutics Market Competition by Key Manufacturers

8.1. Global Brain Tumor Diagnosis and Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Brain Tumor Diagnosis and Therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. GE Healthcare

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Hitachi

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Philips Healthcare

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Siemens Healthineers

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Toshiba Corporation

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Fujifilm Corporation

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Shimadzu Corporation

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Merck & Co.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. AstraZeneca

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Bristol Myer Squibb

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Novartis

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Roche Diagnostics

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Brain Tumor Diagnosis and Therapeutics Market

Figure 4: Global Brain Tumor Diagnosis and Therapeutics Market: Drivers

Figure 5: Global Brain Tumor Diagnosis and Therapeutics Market: Challenges

Figure 6: Global Brain Tumor Diagnosis and Therapeutics Market: Trends

Figure 7: Global Brain Tumor Diagnosis and Therapeutics Market: Opportunity

Figure 8: Global Brain Tumor Diagnosis and Therapeutics Market: Restraint

Figure 9: Global Brain Tumor Diagnosis and Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Brain Tumor Diagnosis and Therapeutics Market Value (USD Million) By Region

Figure 15: Global Brain Tumor Diagnosis and Therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Brain Tumor Diagnosis and Therapeutics Market Value (USD Million) By Region

Figure 23: Global Brain Tumor Diagnosis and Therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Brain Tumor Diagnosis and Therapeutics Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Brain Tumor Diagnosis and Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Brain Tumor Diagnosis and Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Brain Tumor Diagnosis and Therapeutics Market Value (USD Million) By Region

Table 10: Global Brain Tumor Diagnosis and Therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Brain Tumor Diagnosis and Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Brain Tumor Diagnosis and Therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Brain Tumor Diagnosis and Therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: GE Healthcare Basic Information And Sales Area

Table 31: GE Healthcare. Products Portfolio

Table 32: Hitachi Basic Information And Sales Area

Table 33: Hitachi. Products Portfolio

Table 34: Philips Healthcare Basic Information And Sales Area

Table 35: Philips Healthcare. Products Portfolio

Table 36: Siemens Healthineers Basic Information And Sales Area

Table 37: Siemens Healthineers. Products Portfolio

Table 38: Toshiba Corporation Basic Information And Sales Area

Table 39: Toshiba Corporation. Products Portfolio

Table 40: Fujifilm Corporation Basic Information And Sales Area

Table 41: Fujifilm Corporation. Products Portfolio

Table 42: Shimadzu Corporation Basic Information And Sales Area

Table 43: Shimadzu Corporation. Products Portfolio

Table 44: Merck & Co. Basic Information And Sales Area

Table 45: Merck & Co.. Products Portfolio

Table 46: AstraZeneca Basic Information And Sales Area

Table 47: AstraZeneca. Products Portfolio

Table 48: Bristol Myer Squibb Basic Information And Sales Area

Table 49: Bristol Myer Squibb. Products Portfolio

Table 50: Novartis Basic Information And Sales Area

Table 51: Novartis. Products Portfolio

Table 52: Roche Diagnostics Basic Information And Sales Area

Table 53: Roche Diagnostics. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Type

Table 55: Global Market Share (%) By Type (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Brain Tumor Diagnosis and Therapeutics Market Value (USD Million) By Region

Table 59: Global Brain Tumor Diagnosis and Therapeutics Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Type

Table 62: North America Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Type

Table 65: Europe Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Type

Table 71: South America Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Brain Tumor Diagnosis and Therapeutics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	21.77 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GE Healthcare; Hitachi; Philips Healthcare; Siemens Healthineers; Toshiba Corporation; Fujifilm Corporation; Shimadzu Corporation; Merck & Co.; AstraZeneca; Bristol Myer Squibb; Novartis; Roche Diagnostics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options